期刊
BRITISH JOURNAL OF CANCER
卷 120, 期 11, 页码 1033-1036出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41416-019-0466-x
关键词
-
类别
资金
- Clinical Lecturer Starter Grant - Academy of Medical Sciences (AMS Grant) [SGL013/1021]
- AMS
- Wellcome Trust
- Medical Research Council
- British Heart Foundation
- Arthritis Research UK
- Royal College of Physicians
- Diabetes UK
- Cancer Research UK [C57701/A26137]
Programmed cell death ligand-1 immunohistochemical detection (PD-L1 IHC) is a putative predictor of response to PD-1/PD-L1targeted checkpoint inhibitors. However, there is no gold standard assay in hepatocellular carcinoma (HCC). We evaluated 5 PD-L1 IHC assay platforms (E1LN3, 28-8, 22c3, SP263 and SP142) in 100 HCCs reporting PD-L1 expression in malignant (M) and tumourinfiltrating immune cells (TICs) and non-tumorous cirrhotic tissues (NTICs). We found substantial inter-assay heterogeneity in detecting PD-L1 expression in M (R-2 = 0.080-0.921), TICs (Cohen's kappa = 0.175-0.396) and NTICs (kappa = 0.004-0.505). Such diversity may impact on the reliability and reproducibility of PD-L1 IHC assays as a predictor of response to immune checkpoint inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据